Natera, Inc. (NASDAQ:NTRA) Insider Sells $4,101,319.17 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 24,861 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the completion of the transaction, the insider now owns 140,684 shares of the company’s stock, valued at $23,208,639.48. This trade represents a 15.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The shares were sold at an average price of $166.59, for a total value of $809,294.22.
• On Monday, October 28th, Solomon Moshkevich sold 1,196 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $141,379.16.

Natera Stock Down 2.5 %

Shares of NASDAQ:NTRA traded down $4.21 during mid-day trading on Friday, reaching $167.61. 909,104 shares of the stock were exchanged, compared to its average volume of 1,393,352. The stock’s 50 day simple moving average is $166.20 and its 200-day simple moving average is $136.07. Natera, Inc. has a one year low of $62.96 and a one year high of $183.00. The company has a market cap of $22.13 billion, a P/E ratio of -95.23 and a beta of 1.65. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same period last year, the business earned ($0.95) EPS. The business’s quarterly revenue was up 63.9% on a year-over-year basis. As a group, equities research analysts predict that Natera, Inc. will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Blue Trust Inc. increased its position in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc boosted its stake in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares during the period. Quarry LP increased its holdings in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares during the last quarter. Covestor Ltd lifted its holdings in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on NTRA. Leerink Partners boosted their price target on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Morgan Stanley upped their target price on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Craig Hallum raised their price target on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Sanford C. Bernstein upped their price objective on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, January 10th. Finally, StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $162.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.